{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:55:37Z","timestamp":1770134137577,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.yexcr.2017.08.036","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T04:49:58Z","timestamp":1504327798000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interleukin 10 enhanced CD8+ T cell activity and reduced CD8+ T cell apoptosis in patients with diffuse large B cell lymphoma"],"prefix":"10.1016","volume":"360","author":[{"given":"Huiying","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2017.08.036_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/10428190701882187","article-title":"Current treatment approaches for diffuse large B-cell lymphoma","volume":"49","author":"Illidge","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.yexcr.2017.08.036_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.yexcr.2017.08.036_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib4","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.yexcr.2017.08.036_bib5","first-page":"709","article-title":"Inhibition of interleukin 10 by Rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2017.08.036_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1415","article-title":"Opinion: inflammation and necrosis promote tumour growth","volume":"4","author":"Vakkila","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib7","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2017.08.036_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","article-title":"IL-10: master switch from tumor-promoting inflammation to antitumor immunity","volume":"2","author":"Oft","year":"2014","journal-title":"Cancer Immunol. Res. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.yexcr.2017.08.036_bib9","first-page":"2143","article-title":"Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ","volume":"98","author":"Fujii","year":"2001","journal-title":"Blood Am. Soc. Hematol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexcr.2017.08.036_bib11","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","article-title":"IL-10 directly activates and expands tumor-resident CD8+ T cells without De Novo infiltration from secondary lymphoid organs","volume":"72","author":"Emmerich","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2017.08.036_bib12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/bies.201300004","article-title":"Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-\u03b3-mediated CD8(+) T cell cytotoxicity","volume":"35","author":"Mumm","year":"2013","journal-title":"Bioessays"},{"key":"10.1016\/j.yexcr.2017.08.036_bib13","first-page":"3642","article-title":"Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis","volume":"186","author":"Trandem","year":"2011","journal-title":"J. Immunol. Am. Assoc. Immunol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-06-508267","article-title":"A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency","volume":"122","author":"Neven","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2017.08.036_bib15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.yexcr.2017.08.036_bib16","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J. Clin. Investig. Am. Soc. Clin. Investig."},{"key":"10.1016\/j.yexcr.2017.08.036_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.yexcr.2017.08.036_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.yexcr.2017.08.036_bib19","first-page":"10761","article-title":"Akt\/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein","volume":"275","author":"Pugazhenthi","year":"2000","journal-title":"J. Biol. Chem. Am. Soc. Biochem. Mol. Biol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib20","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.4049\/jimmunol.1100102","article-title":"Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim","volume":"186","author":"Kurtulus","year":"2011","journal-title":"J. Immunol. NIH Public Access"},{"key":"10.1016\/j.yexcr.2017.08.036_bib21","first-page":"5499","article-title":"Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors","volume":"56","author":"Voorzanger","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2017.08.036_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T Cell Therapy for Lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu. Rev. Med. Annu. Rev."},{"key":"10.1016\/j.yexcr.2017.08.036_bib23","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1038\/cti.2014.11","article-title":"Adoptive T-cell therapy: adverse events and safety switches","volume":"3","author":"Tey","year":"2014","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib24","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig. Am. Soc. Clin. Investig."},{"key":"10.1016\/j.yexcr.2017.08.036_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2017.08.036_bib26","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.4049\/jimmunol.164.8.3950","article-title":"Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells","volume":"164","author":"Grayson","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2017.08.036_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20071641","article-title":"Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates","volume":"205","author":"Sarkar","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexcr.2017.08.036_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3858\/emm.2009.41.2.012","article-title":"STAT3 is involved in phosphatidic acid-induced Bcl-2 expression in HeLa cells","volume":"41","author":"Choi","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.yexcr.2017.08.036_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.cdd.4402007","article-title":"BCL-2 expression is mainly regulated by JAK\/STAT3 pathway in human CD34+ hematopoietic cells","volume":"14","author":"Sep\u00falveda","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2017.08.036_bib30","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482717304573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482717304573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T18:51:50Z","timestamp":1575399110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482717304573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0014482717304573"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2017.08.036","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin 10 enhanced CD8+ T cell activity and reduced CD8+ T cell apoptosis in patients with diffuse large B cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2017.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}